Portable Detection Of Serum HER-2 In Breast Cancer By A Pressure-based Platform

Background and ObjectiveHigh serum HER-2 extracellular domain（sHER-2 ECD）level has a reverse association with tumor behaviors.The conventional methods for sHER-2detection have disadvantages with high cost,heavy equipment and user-unfriendly.In this study,a portable platform for HER-2 detection has been established by the pressure-based bioassay.Materials and MethodsThe pressure bioassay consists of a monoclonal antibody immobilized on 8-well strip plate,the analyte HER-2,and another monoclonal antibody labeled with the Pt nanoparticles（PtNPs）,which have the catalytic ability to decompose H₂O₂ into H₂O and O₂.Moreover,34 serum samples were collected from 30 breast cancer patients to validate the performance of the pressure bioassay.ResultsThe pressure bioassay platform of HER-2 showed a dynamic range from 2-50ng/mL with a limited of detection（LOD）of 2 ng/mL,which was consistent with ELISA.In the 34 real serum samples,there were significant correlation between sHER-2 ECD level and several clinicopathological parameters,especially tissue HER-2 status.The sHER-2 ECD level that detected by the pressure assay was found to be decreased after target-therapy in a patient with tHER-2 positive.ConclusionA pressure-based bioassay has been performed to detect serum HER-2 with sensitivity,portability and user friendly,which could facilitate breast cancer diagnosis and prognosis in clinical laboratory and resource limited area.